PUBLISHER: BCC Research | PRODUCT CODE: 1416213
PUBLISHER: BCC Research | PRODUCT CODE: 1416213
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
The global market for clinical applications of next-generation sequencing for cancer is estimated to increase from $11.2 billion in 2023 to reach $29.6 billion by 2028, at a CAGR of 21.6% from 2023 through 2028.
The global market for clinical applications of next-generation sequencing for non-cancerous diseases is estimated to increase from $10.7 billion in 2023 to reach nearly $23.3 billion by 2028, at a CAGR of 16.8% from 2023 through 2028.
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.
Specific geographic markets are discussed, namely North America, Europe, Asia-Pacific, and the Rest of the World.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing.
More than 100 companies in the clinical NGS industry are profiled in this report.
BCC Research also provides a summary of the recent, primary industry acquisitions and strategic alliances, including key alliance trends.
Table A : Scope of the Report